These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 31104458)
21. Eltrombopag in refractory aplastic anemia. Akard L N Engl J Med; 2012 Sep; 367(12):1162-3; author reply 1163. PubMed ID: 22992085 [No Abstract] [Full Text] [Related]
22. Eltrombopag in refractory aplastic anemia. Oshima Y; Yuji K; Tojo A N Engl J Med; 2012 Sep; 367(12):1162; author reply 1163. PubMed ID: 22992084 [No Abstract] [Full Text] [Related]
23. Consideration of ATG-free therapy with eltrombopag and cyclosporine for severe aplastic anaemia. Groarke EM Lancet Haematol; 2024 Mar; 11(3):e173-e174. PubMed ID: 38335977 [No Abstract] [Full Text] [Related]
24. Severe cutaneous toxicity related to Eltrombopag. Meyer SC; Rovó A; Tsakiris DA; Scherer K; Tichelli A; Holbro A Br J Haematol; 2013 Feb; 160(3):412-4. PubMed ID: 23151239 [No Abstract] [Full Text] [Related]
25. Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. Lambert MP; Witmer CM; Kwiatkowski JL Am J Hematol; 2017 Jun; 92(6):E88-E91. PubMed ID: 28240793 [No Abstract] [Full Text] [Related]
26. Eltrombopag mobilizes iron in patients with aplastic anemia. Zhao Z; Sun Q; Sokoll LJ; Streiff M; Cheng Z; Grasmeder S; Townsley DM; Young NS; Dunbar CE; Winkler T Blood; 2018 May; 131(21):2399-2402. PubMed ID: 29632023 [No Abstract] [Full Text] [Related]
29. Eltrombopag (Revolade ) and thrombocytopenia in patients with hepatitis C. Hepatotoxic drug; more harms than benefits. Prescrire Int; 2015 Sep; 24(163):208-9. PubMed ID: 26417629 [TBL] [Abstract][Full Text] [Related]
30. Eltrombopag for the treatment of aplastic anemia: current perspectives. Lum SH; Grainger JD Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288 [TBL] [Abstract][Full Text] [Related]
31. Eltrombopag in chronic idiopathic thrombocytopenic purpura. Panzer S; Pabinger I Lancet; 2009 Feb; 373(9664):607-8. PubMed ID: 19231614 [No Abstract] [Full Text] [Related]
32. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia. Geng W; Kearney S; Nelson S Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285 [TBL] [Abstract][Full Text] [Related]
33. Activity of eltrombopag in severe aplastic anemia. Scheinberg P Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):450-456. PubMed ID: 30504345 [TBL] [Abstract][Full Text] [Related]
34. Molecule of the month. Eltrombopag. Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592 [No Abstract] [Full Text] [Related]
38. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia. Gill H; Leung GM; Lopes D; Kwong YL Br J Haematol; 2017 Mar; 176(6):991-994. PubMed ID: 27097929 [No Abstract] [Full Text] [Related]
39. Activity of eltrombopag in severe aplastic anemia. Scheinberg P Blood Adv; 2018 Nov; 2(21):3054-3062. PubMed ID: 30425070 [TBL] [Abstract][Full Text] [Related]
40. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Lengline E; Drenou B; Peterlin P; Tournilhac O; Abraham J; Berceanu A; Dupriez B; Guillerm G; Raffoux E; de Fontbrune FS; Ades L; Balsat M; Chaoui D; Coppo P; Corm S; Leblanc T; Maillard N; Terriou L; Socié G; de Latour RP Haematologica; 2018 Feb; 103(2):212-220. PubMed ID: 29170252 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]